862508-03-0

Basic information

• Product Name: penthyl(5-fluro-2-oxo-1, 2-dihydropyriMidin-4-yl) carbaMate
• Synonyms: penthyl(5-fluro-2-oxo-1, 2-dihydropyriMidin-4-yl) carbaMate;(5-Fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)carbamic acid pentyl ester;Pentyl (5-fluoro-2-oxo-1,2-dihydro-4-pyrimidinyl)carbamate;Pentyl (5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate
• CAS NO: 862508-03-0
• Molecular Formula: C₁₀H₁₄FN₃O₃
• Molecular Weight: 243.2348632
• Mol File: 862508-03-0.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: penthyl(5-fluro-2-oxo-1, 2-dihydropyriMidin-4-yl) carbaMate(CAS DataBase Reference)
• NIST Chemistry Reference: penthyl(5-fluro-2-oxo-1, 2-dihydropyriMidin-4-yl) carbaMate(862508-03-0)
• EPA Substance Registry System: penthyl(5-fluro-2-oxo-1, 2-dihydropyriMidin-4-yl) carbaMate(862508-03-0)

Safety Data

• Hazardous Substances Data: 862508-03-0(Hazardous Substances Data)

Usage

Description

Pentyl(5-fluro-2-oxo-1,2-dihydropyriMidin-4-yl) carbaMate is a chemical compound that is a derivative of fluorocytosine, which is an antimicrobial agent. It is characterized by its unique molecular structure that includes a pentyl ester group and a 5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl moiety. penthyl(5-fluro-2-oxo-1, 2-dihydropyriMidin-4-yl) carbaMate has potential applications in various industries due to its properties.

Uses

Used in Agricultural Industry:
Pentyl(5-fluro-2-oxo-1,2-dihydropyriMidin-4-yl) carbaMate is used as a fungicide for the control of plant pathogens. It serves as an effective agent in protecting crops from various fungal infections, ensuring better crop yield and quality.
As a derivative of fluorocytosine, penthyl(5-fluro-2-oxo-1,2-dihydropyriMidin-4-yl) carbaMate leverages the antimicrobial properties of its parent compound, making it a valuable asset in the agricultural sector for managing plant diseases and maintaining a healthy growing environment.

InChI:InChI=1S/C10H14FN3O3/c1-2-3-4-5-17-10(16)14-8-7(11)6-12-9(15)13-8/h6H,2-5H2,1H3,(H2,12,13,14,15,16)

Upstream product

• 638-41-5 pentyl chloroformate 
• 2341-22-2 5-fluorocytidine 
• 2022-85-7 Flucytosine 

Downstream Products

• 162204-20-8 N¹-(2',3'-di-O-acetyl-5'-deoxy-β-D-ribofuranosyl)-5-fluoro-N⁴-(pentyloxycarbonyl)cytosine 
• 154361-50-9 capecitabine 

Relevant articles and documents

Preparation method of capecitabine impurity (5-fluoro-2-oxo-1,2-dihydropyrimidine-4-yl)amylcarbamate

The invention discloses a preparation method of a capecitabine impurity (5-fluoro-2-oxo-1,2-dihydropyrimidine-4-yl)amylcarbamate. According to the method, 5-flucytosine and n-amyl chloroformate reactin an organic solvent to produce (5-fluoro-2-oxo-1,2-dihydropyrimidine-4-yl)amylcarbamate with pyridine as an acid binding agent and tetrabutylammonium bromide as a phase transfer catalyst. The preparation method comprises simple steps, the yield (90% or higher) is high, and the prepared product has higher purity (99% or higher) and can be completely used as an impurity reference substance to be used for quality research of capecitabine.

Capecitabine preparation method

The invention discloses a capecitabine preparation method; 5-FU as a raw material is subjected to a reaction with pentyloxy formyl chloride, then an intermediate is generated and then is coupled with a ribose derivative, an ethoxyl protective group of ethoxyl of the ribose derivative is removed in the coupling reaction, and thus the target compound capecitabine is obtained; the method comprises the following steps: step one, the 5-FU as the raw material is subjected to the reaction with pentyloxy formyl chloride, and then the intermediate is generated; and step two, the intermediate is coupled with the ribose derivative to generate the product capecitabine. The production cost can be saved, the medical expense of patients is reduced, the side effect is reduced, and the yield is higher.

METHOD FOR THE PREPARATION OF CAPECITABINE AND INTERMEDIATES USED IN SAID METHOD

A process to obtain capecitabine compound and its pharmaceutically acceptable derivatives is hereby disclosed. Likewise, novel intermediates to be used in the preparation of capecitabine compound and its pharmaceutically acceptable derivatives are also disclosed. The procedure comprises the stage of causing a reaction of N4-(n-pentyloxycarbonyl))-5- fluorocytosine with (1,2,3-tri-O-acetyl-5-deoxy- α,β-D-ribofuranose.